SER 155
Alternative Names: SER-155Latest Information Update: 05 Jun 2025
At a glance
- Originator Seres Therapeutics
- Developer Memorial Sloan-Kettering Cancer Center; Seres Therapeutics
- Class Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Bacteraemia; Enterocolitis; Graft-versus-host disease; Intra-abdominal infections
Most Recent Events
- 27 May 2025 Pharmacodynamics data from a phase-Ib trial in Graft-versus-host disease released by Seres Therapeutics
- 15 May 2025 Seres Therapeutics plans a phase III trial (PO)
- 03 Mar 2025 Seres Therapeutics anticipates submitting a proposed protocol for a clinical trial of SER 155 in allo-HSCT to the US FDA, in the second quarter of 2025